Literature DB >> 20689952

Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death.

Bettina M Kaminski1, Andreas Weigert, Bernhard Brüne, Marco Schumacher, Uwe Wenzel, Dieter Steinhilber, Jürgen Stein, Sandra Ulrich.   

Abstract

The objective of this study was to investigate, whether the plant-derived isothiocyanate Sulforaphane (SFN) enhances the antitumor activities of the chemotherapeutic agent oxaliplatin (Ox) in a cell culture model of colorectal cancer. Caco-2 cells were cultured under standard conditions and treated with increasing concentrations of SFN [1-20 μM] and/or Ox [100 nM-10 μM]. For co-incubation, cells were pre-treated with SFN for 24 h. Cell growth was determined by BrdU incorporation. Drug interactions were assessed using the combination-index method (CI) (Cl < 1 indicates synergism). Apoptotic events were characterized by different ELISA techniques. Protein levels were examined by Western blot analysis. Annexin V- and propidium iodide (PI) staining followed by FACS analysis was used to differentiate between apoptotic and necrotic events. SFN and Ox alone inhibited cell growth of Caco-2 cells in a dose-dependent manner, an effect, which could be synergistically enhanced, when cells were incubated with the combination of both agents. Co-treated cells further displayed distinctive morphological changes that occurred during the apoptotic process, such as cell surface exposure of phosphatidylserine, membrane blebbing as well as the occurence of cytoplasmic histone-associated DNA fragments. Further observations thereby pointed toward simultaneous activation of both extrinsic and intrinsic apoptotic pathways. With increasing concentrations and treatment duration, a shift from apoptotic to necrotic cell death could be observed. In conclusion, the data suggest that the isothiocyanate SFN sensitizes colon cancer cells to Ox-induced cell growth inhibition via induction of different modes of cell death.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689952     DOI: 10.1007/s00280-010-1413-y

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

Review 1.  Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition.

Authors:  Stephanie M Tortorella; Simon G Royce; Paul V Licciardi; Tom C Karagiannis
Journal:  Antioxid Redox Signal       Date:  2014-12-19       Impact factor: 8.401

2.  The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review.

Authors:  Reza Bayat Mokhtari; Narges Baluch; Tina S Homayouni; Evgeniya Morgatskaya; Sushil Kumar; Parandis Kazemi; Herman Yeger
Journal:  J Cell Commun Signal       Date:  2017-07-23       Impact factor: 5.782

3.  Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy.

Authors:  Sajad Fakhri; Seyed Zachariah Moradi; Akram Yarmohammadi; Fatemeh Narimani; Carly E Wallace; Anupam Bishayee
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

Review 4.  Research progress on chemopreventive effects of phytochemicals on colorectal cancer and their mechanisms.

Authors:  Teng-Fei Yin; Min Wang; Ying Qing; Ying-Min Lin; Dong Wu
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

Review 5.  Molecular targets of isothiocyanates in cancer: recent advances.

Authors:  Parul Gupta; Bonglee Kim; Sung-Hoon Kim; Sanjay K Srivastava
Journal:  Mol Nutr Food Res       Date:  2014-02-10       Impact factor: 5.914

Review 6.  Role of 4-hydroxynonenal in chemopreventive activities of sulforaphane.

Authors:  Rajendra Sharma; Abha Sharma; Pankaj Chaudhary; Mukesh Sahu; Shailesh Jaiswal; Sanjay Awasthi; Yogesh C Awasthi
Journal:  Free Radic Biol Med       Date:  2012-04-23       Impact factor: 7.376

7.  Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy.

Authors:  Michal Pastorek; Veronika Simko; Martina Takacova; Monika Barathova; Maria Bartosova; Luba Hunakova; Olga Sedlakova; Sona Hudecova; Olga Krizanova; Franck Dequiedt; Silvia Pastorekova; Jan Sedlak
Journal:  Int J Oncol       Date:  2015-05-05       Impact factor: 5.650

Review 8.  Broad targeting of resistance to apoptosis in cancer.

Authors:  Ramzi M Mohammad; Irfana Muqbil; Leroy Lowe; Clement Yedjou; Hsue-Yin Hsu; Liang-Tzung Lin; Markus David Siegelin; Carmela Fimognari; Nagi B Kumar; Q Ping Dou; Huanjie Yang; Abbas K Samadi; Gian Luigi Russo; Carmela Spagnuolo; Swapan K Ray; Mrinmay Chakrabarti; James D Morre; Helen M Coley; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; William G Helferich; Xujuan Yang; Chandra S Boosani; Gunjan Guha; Dipita Bhakta; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; W Nicol Keith; Alan Bilsland; Dorota Halicka; Somaira Nowsheen; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2015-04-28       Impact factor: 15.707

9.  Synergistic Interaction between 5-FU and an Analog of Sulforaphane-2-Oxohexyl Isothiocyanate-In an In Vitro Colon Cancer Model.

Authors:  Małgorzata Milczarek; Anna Pogorzelska; Katarzyna Wiktorska
Journal:  Molecules       Date:  2021-05-19       Impact factor: 4.411

10.  The Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent Interactions.

Authors:  Lidia Śliwka; Katarzyna Wiktorska; Piotr Suchocki; Małgorzata Milczarek; Szymon Mielczarek; Katarzyna Lubelska; Tomasz Cierpiał; Piotr Łyżwa; Piotr Kiełbasiński; Anna Jaromin; Anna Flis; Zdzisław Chilmonczyk
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.